HIV specialist firm ViiV Healthcare has announced a new deal with Japan’s Shionogi on a promising new treatment.
ViiV Healthcare was established in 2009 as a joint venture between GlaxoSmithKline and Pfizer, with GSK holding an 85% stake and Pfizer taking a 15% share.
Now Shionogi will gain a 10% share in ViiV in exchange for handing over rights to the drug, integrase inhibitor dolutegravir and other early-stage drugs in the same class.